指南与共识MDS 与骨髓增殖性肿瘤

成人骨髓增生异常综合征的指南衍生指标

Guideline-based indicators for adult patients with myelodysplastic syndromes.
指南 / 共识 · Blood Adv · 2020-01-01

该研究通过筛查1999年至2018年发布的骨髓增生异常综合征(MDS)相关指南与推荐,汇总候选指标并组建国际多学科专家组进行共识评分,最终确定涵盖诊断、治疗和提供者/基础设施三个领域的29项指南衍生指标(GBIs),用于标准化评估成人MDS患者的医疗质量。

要点

  • 最终确定29项GBIs,包括诊断14项、治疗8项、提供者/基础设施7项。
  • 专家组包括17名MDS专家、7名卫生专业人员和5名患者代表。
  • 患者报告结局、毒性和老年评估的标准化存在不足,需未来优化。

核心结论

  • 这些GBIs是首个关于可测量要素的全面共识,涉及最佳实践绩效、结局和结构资源,可作为标准化工具用于评估、比较和促进成人MDS日常诊疗中的良好医疗质量。

研究设计与样本

  • 研究筛查1999年至2018年发布的相关指南与推荐,汇总候选GBIs并形成正式手册,组建国际多学科专家组(MDS专家17名、卫生专业人员7名、患者代表5名)进行共识评分。

主要发现

  • 专家组第一轮反馈率为82%(28人中23人),第二轮为96%(27人中26人)。
  • 最终29项GBIs达到预定义的选择同意评分(>70%),涵盖诊断(14项)、治疗(8项)和提供者/基础设施特征(7项)三个领域。
  • 研究识别出患者报告结局、毒性和老年评估标准化方面的不足,需未来优化。

关键数值与推荐

  • 最终GBIs共29项,诊断领域14项、治疗领域8项、提供者/基础设施领域7项,选择同意评分阈值为>70%。

临床怎么用

  • 这些GBIs可作为标准化工具,用于临床开发周期内评估、比较和促进成人MDS日常诊疗中的良好医疗质量。

局限性

  • 患者报告结局、毒性和老年评估的标准化存在不足,需在未来优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic syndromes (MDSs) represent a heterogeneous group of hematological stem cell disorders with an increasing burden on health care systems. Evidence-based MDS guidelines and recommendations (G/Rs) are published but do not necessarily translate into better quality of care if adherence is not maintained in daily clinical practice. Guideline-based indicators (GBIs) are measurable elements for the standardized assessment of quality of care and, thus far, have not been developed for adult MDS patients. To this end, we screened relevant G/Rs published between 1999 and 2018 and aggregated all available information as candidate GBIs into a formalized handbook as the basis for the subsequent consensus rating procedure. An international multidisciplinary expert panel group (EPG) of acknowledged MDS experts (n = 17), health professionals (n = 7), and patient advocates (n = 5) was appointed. The EPG feedback rates for the first and second round were 82% (23 of 28) and 96% (26 of 27), respectively. A final set of 29 GBIs for the 3 domains of diagnosis (n = 14), therapy (n = 8), and provider/infrastructural characteristics (n = 7) achieved the predefined agreement score for selection (>70%). We identified shortcomings in standardization of patient-reported outcomes, toxicity, and geriatric assessments that need to be optimized in the future. Our GBIs represent the first comprehensive consensus on measurable elements addressing best practice performance, outcomes, and structural resources. They can be used as a standardized instrument with the goal of assessing, comparing, and fostering good quality of care within clinical development cycles in the daily care of adult MDS patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Stojkov K, Silzle T, Stussi G, et al. Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020. PMID: 32841339. doi:10.1182/bloodadvances.2020002314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。